Yahoo Αναζήτηση Διαδυκτίου

ETF Daily News

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $132.83 Consensus Price Target from Brokerages

Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) have earned a consensus recommendation of “Buy” from the six brokerages that are covering the company, Marketbeat.com reports.

2 ημέρες Πριν από

ETF Daily News

Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $125.00 at Barclays

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) had its price objective raised by Barclays from $110.00 to $125.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock.

3 ημέρες Πριν από

Business Insider

Strategic Growth and Revenue Potential Drive Buy Rating for Ligand Pharma

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Ligand Pharma (LGND – Research Report). The associated

1 ημέρα Πριν από

Business Insider

Ligand price target raised to $125 from $110 at Barclays

Barclays analyst Balaji Prasad raised the firm’s price target on Ligand (LGND) to $125 from $110 and keeps an Overweight rating on the

5 ημέρες Πριν από

Benzinga.com

Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know

Analysts have recently evaluated Ligand Pharmaceuticals and provided 12-month price targets. The average target is $133.71, accompanied by a high estimate of $157.00 and a low estimate of $110.00. Surpassing the previous average price target of $128.60, the current average has increased by 3.97%.

2 εβδομάδες Πριν από